感染疾病治療藥物市場規模、佔有率、成長分析、按類型、治療方法、地區 - 產業預測，2024-2031

2022年全球感染疾病藥物市場規模估值為1,168億美元，從2023年的1,217.1億美元成長到2031年的1,691.4億美元，預計在複合預測期內（2024-2031年）將持續成長。年增率為4.2%）。

全球醫療保健產業繼續面臨由病毒和細菌等多種病原體引起的感染疾病的巨大挑戰。儘管診斷、治療方法和疫苗接種等預防措施取得了進步，降低了死亡率，但這些疾病的復發仍然是一個重大的公共衛生問題。因此，由於感染率上升、早期診斷意識增強以及政府和私人組織研究經費的增加，感染疾病藥物市場預計將顯著成長。然而，先進的治療方法價格昂貴，限制了許多患者的使用，並對市場擴張構成了挑戰。此外，人們越來越偏愛價格實惠的學名藥，這威脅到了控制感染疾病的品牌療法的成長。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 技術進步
• 監管環境
• 案例研究

感染疾病治療藥物市場規模：按類型和複合年成長率（2024-2031）

• 市場概況
• HIV
• 肝炎
• 流感
• 結核
• 瘧疾
• HPV

感染疾病治療藥物市場規模：依治療方法及複合年成長率（2024-2031）

• 市場概況
• 抗生素
• 抗真菌藥物
• 抗病毒藥物
• 其他

感染疾病治療藥物市場規模：依最終用戶及複合年成長率（2024-2031）

• 市場概況
• 醫院
• 診所

感染疾病治療藥物市場規模：按地區及複合年成長率（2024-2031）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Gilead Sciences
• GlaxoSmithKline（GSK）
• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson（Janssen Pharmaceuticals）
• BioCryst Pharmaceuticals Inc.
• Boehringer Ingelheim GmbH
• AbbVie Inc.
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb（BMS）
• Moderna, Inc.
• Regeneron Pharmaceuticals
• Vertex Pharmaceuticals
• Vir Biotechnology, Inc.
• Eli Lilly and Company
• Amgen Inc.

結論和建議

Global Infectious Disease Therapeutics Market size was valued at USD 116.8 billion in 2022 and is poised to grow from USD 121.71 billion in 2023 to USD 169.14 billion by 2031, growing at a CAGR of 4.2% during the forecast period (2024-2031).

The global healthcare sector continues to face immense challenges due to infectious diseases, which are triggered by a range of pathogens including viruses and bacteria. Despite progress in diagnostics, treatment methods, and preventive measures like vaccinations that have lowered mortality rates, the resurgence of these diseases remains a critical public health issue. Consequently, the infectious disease therapeutics market is poised for considerable growth, driven by rising infection rates, heightened awareness for early diagnosis, and increased funding for research from governmental and private entities. Nonetheless, the expensive nature of advanced treatments poses a challenge for market expansion, limiting access for many patients. Additionally, the growing preference for affordable generic medications threatens the growth of branded therapeutics aimed at combating infectious diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infectious Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Infectious Disease Therapeutics Market Segmental Analysis

Global Infectious Disease Therapeutics Market is segmented by type, treatment, end users and region. Based on type, the market is segmented into HIV, hepatitis, influenza, TB, malaria and HPV. Based on treatment, the market is segmented into antibacterial, antifungal drugs, antiviral drugs and others. Based on end users, the market is segmented into hospitals and clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Infectious Disease Therapeutics Market

The global infectious disease therapeutics market is likely to experience significant growth due to several driving factors. An increase in investment aimed at improving access to treatments for infectious diseases, along with strategic initiatives to raise awareness regarding both the treatments and diagnostics of these conditions, will contribute positively to market expansion. Furthermore, there has been a noticeable rise in clinical trial research dedicated to the development of innovative pharmaceutical solutions. Collectively, these elements are expected to propel the demand for infectious disease therapeutics, shaping a promising outlook for the market in the coming years.

Restraints in the Global Infectious Disease Therapeutics Market

The growth of the Global Infectious Disease Therapeutics market may be hindered by several factors, particularly the lack of awareness regarding available treatment options. In many developing nations, there is insufficient adoption of these therapies, compounded by limited reimbursement options for specific infectious diseases. This combination of inadequate understanding and accessibility can significantly restrain the market's expansion throughout the projected timeframe, as healthcare providers and patients may not fully utilize or access the innovative treatments necessary to combat these diseases effectively. Consequently, addressing these challenges is crucial for the market to reach its full potential in the coming years.

Market Trends of the Global Infectious Disease Therapeutics Market

The Global Infectious Disease Therapeutics market is witnessing significant growth, driven by the rising prevalence of malaria, particularly in developing regions such as India, Africa, and Southeast Asia. This surge is further fueled by increased research and development efforts from key pharmaceutical manufacturers and healthcare organizations aimed at advancing therapeutic options. Innovations in drug formulations and delivery methodologies, coupled with heightened awareness and funding for infectious disease management, are propelling the market forward. Additionally, strategic collaborations and partnerships in the healthcare sector are expected to enhance access to effective treatments, thereby shaping a robust market landscape in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Infectious Disease Therapeutics Market Size by Type & CAGR (2024-2031)

• Market Overview
• HIV
• Hepatitis
• Influenza
• TB
• Malaria
• HPV

Global Infectious Disease Therapeutics Market Size by Treatment & CAGR (2024-2031)

• Market Overview
• Antibacterial
• Antifungal Drugs
• Antiviral Drugs
• Others

Global Infectious Disease Therapeutics Market Size by End Users & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics

Global Infectious Disease Therapeutics Market Size & CAGR (2024-2031)

• North America (Type, Treatment, End Users)
  • USA
  • Canada
• Europe (Type, Treatment, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen Pharmaceuticals)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioCryst Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (BMS)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vir Biotechnology, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations